Retrospective Study
Copyright ©The Author(s) 2021.
World J Gastrointest Surg. Mar 27, 2021; 13(3): 279-302
Published online Mar 27, 2021. doi: 10.4240/wjgs.v13.i3.279
Table 4 Univariate analysis for overall survival in pancreatic ductal adenocarcinoma patients undergoing radical R0 resection
Characteristic
HR (95%CI)
P value
Age (yr)1.358 (1.036-1.780)0.027
> 60
≤ 60
Sex1.281 (0.979-1.675)0.071
Male
Female
Blood type0.579
A
B
AB
O
Diabetes0.903 (0.676-1.206)0.491
Absent
Present
Smoking status0.866 (0.635-1.181)0.363
Absent
Present
Alcohol consumption1.083 (0.754-1.556)0.667
Absent
Present
Family history of cancer1.251 (0.617-2.537)0.535
Absent
Present
Clinical symptoms0.600 (0.424-0.848)0.004
Absent
Present
Open surgery approach0.954 (0.729-1.249)0.731
Pancreaticoduodenectomy
Distal pancreatectomy with splenectomy
Tumor location0.954 (0.729-1.249)0.731
Head and neck
Body and tail
Degree of differentiation< 0.001
Well
Moderately
Poorly
Lymphovascular invasion0.793 (0.590-1.065)0.123
Absent
Present
Perineural invasion0.905 (0.666-1.231)0.525
Absent
Present
Capsular invasion0.609 (0.420-0.885)0.009
Absent
Present
Maximal tumor diameter (cm)1.403 (1.058-1.862)0.019
> 4
≤ 4
T stage0.035
T1
T2
T3
Lymph node metastasis0.590 (0.449-0.775)< 0.001
Absent
Present
N stage0.001
N0
N1
N2
TNM stage0.003
IA
IB
IIA
IIB
III
Preoperative CA19-9 level (U/mL)1.971 (1.469-2.644)< 0.001
> 336.4
≤ 336.4
Preoperative fibrinogen concentration (g/L)1.888 (1.438-2.479)< 0.001
> 3.31
≤ 3.31
Preoperative D-Dimer concentration (g/L)1.625 (1.244-2.123)< 0.001
> 0.53
≤ 0.53
Adjuvant therapy1.625 (1.244-2.123)< 0.001
Absent
Present